深圳市尚荣医疗股份有限公司 独立董事2024年度述职报告（赵俊峰） （一）个人简介 赵俊峰，本科学历，中国国籍。现任深圳市融创投资顾问有限公司董事长、 总经理，兼任深圳市圣富诺电气有限公司监事，深圳市融创创业投资有限公司总 经理，深圳市融科创创业投资有限公司执行董事，深圳市融创智投资管理有限公 司董事长，深圳市融创兴投资管理有限公司执行董事，总经理，深圳市融创空间 管理有限公司总经理，深圳市融创曦投资管理有限公司执行董事，深圳市融创空 间投资发展有限公司执行董事、总经理，深圳市融创东舟投资发展有限公司总经 理，北京市融创智投资管理有限公司执行董事、总经理、深圳市尚荣医疗股份有 限公司独立董事等职务 （二）独立性情况的说明 本人未在公司担任除独立董事和董事会各专门委员会委员以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关 系或其他可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情 况，符合《上市公司独立董事管理办法》、《深圳证券交易所上市公司自律监管 指引第1号——主板上市公司规范运作》中对独立董事独立性的相关要求。 二、独立董事年度履职情况 2024年度，在 ...

一、独立董事的基本情况 深圳市尚荣医疗股份有限公司 独立董事2024年度述职报告（曾江虹） 2024年，作为深圳市尚荣医疗股份有限公司（以下简称"公司"或"尚荣医 疗"）董事会独立董事，在2024年度任职期间，严格按照《公司法》、《上市公 司独立董事管理办法》、《深圳证券交易所股票上市规则》、《深圳证券交易所 上市公司自律监管指引第1号—主板上市公司规范运作》等法律、法规、规范性 文件和《公司章程》、《公司独立董事工作制度》的规定和要求，勤勉尽责、忠 实履行职责，积极出席相关会议，认真审议各项议案，并本着独立、客观、公正 的立场对公司相关事项发表独立意见，充分发挥独立董事及各专门委员会的作用， 切实维护全体股东尤其是中小股东的合法权益。现将2024年度的工作情况简要汇 报如下： （一）个人简介 本人曾江虹，毕业于澳洲莫道克大学，硕士学位，高级会计师，注册会计师， 注册税务师，已取得深圳证券交易所颁发的独立董事资格证书。现任立信德豪税 务师事务所（深圳）有限公司合伙人，兼任深圳市尚荣医疗股份有限公司独立董 事等职务。 （二）独立性情况的说明 本人未在公司担任除独立董事和董事会各专门委员会委员以外的任何职务， 也 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,448,206,268.39, representing a 21.40% increase compared to ¥1,192,887,048.61 in 2023 [6]. - The net profit attributable to shareholders was ¥22,281,952.68, a significant turnaround from a loss of ¥148,889,156.24 in 2023, marking a 114.97% improvement [6]. - The net cash flow from operating activities surged to ¥120,946,787.47, reflecting a 585.90% increase from ¥17,633,369.87 in the previous year [6]. - The basic earnings per share improved to ¥0.0264 from a loss of ¥0.1762 in 2023, indicating a 114.98% increase [6]. - Operating profit increased to CNY 33,537,300, a significant rise of 127.67% compared to the previous year [55]. - The medical products segment generated revenue of CNY 968,761,029.99, accounting for 66.89% of total revenue, with a growth of 16.49% [58]. - The medical services segment saw revenue of CNY 395,249,151.65, which is a 40.26% increase from the previous year, representing 27.29% of total revenue [58]. - The company achieved total operating revenue of CNY 1,448,206,268.39, representing a year-on-year growth of 21.40% [55]. Market Trends - The total number of medical institutions in China grew by 1.6% to 1.092 million in 2024, indicating a positive trend in the healthcare sector [28]. - The total number of outpatient visits increased by 37.44% to 6.689 billion in 2024, reflecting a growing demand for healthcare services [29]. - In 2023, China's total health expenditure reached CNY 90,575.8 billion, a growth of 6.15% compared to 2022, with government health spending accounting for 26.7% [31]. - The per capita health expenditure in 2023 was CNY 6,425.3, with total health expenditure as a percentage of GDP at 7.2%, an increase of 0.1 percentage points from 2022 [31]. - The hospital logistics service market in China reached CNY 157.17 billion in 2022, representing 85.3% of the total healthcare logistics market, with expectations to expand to a trillion-level market in the coming years [32]. - The low-value medical consumables market size reached CNY 128 billion in 2023, indicating a market scale exceeding CNY 100 billion [32]. - China's medical device market is projected to grow from CNY 630 billion in 2015 to CNY 1,875 billion by 2025, reflecting a cumulative growth of 197.88% and an annual compound growth rate of 11.5% [34]. - The health service industry is projected to reach CNY 16 trillion by 2030, driven by the increasing demand for health services due to rapid economic development and population aging [35]. Corporate Governance - The company has confirmed that all board members attended the meeting to review the annual report [5]. - The board of directors consists of nine members, including three independent directors, and operates in accordance with relevant laws and regulations [131]. - The company has established a performance evaluation and incentive mechanism to create a fair and efficient work environment for employees [132]. - The company emphasizes the importance of maintaining good relationships with stakeholders, including creditors and consumers, to promote sustainable development [132]. - The company adheres to strict information disclosure practices, ensuring timely and accurate communication with investors [132]. - The company has held three shareholder meetings during the reporting period, ensuring compliance with legal requirements and equal treatment of all shareholders [130]. - The company has established a sound governance structure to ensure all shareholders enjoy their rights fairly and transparently [187]. Investment and Funding - The total amount of funds raised through the issuance of convertible bonds is RMB 750 million, with a net amount of RMB 732.35 million after deducting underwriting fees and other expenses [88][89]. - The company has utilized RMB 10.39 million of the raised funds during the reporting period, with a cumulative usage of RMB 411.08 million [89][94]. - The company has established a three-party supervision agreement with banks and underwriters for the management of raised funds [91]. - The total interest accrued on the raised funds amounts to RMB 37.93 million [89]. - The company has not reported any idle funds for over two years [87]. - The company has approved the use of up to RMB 320 million of idle raised funds for cash management, with an expected annual return of 1.9% to 2.34% [98]. - The total amount of idle raised funds used for cash management is RMB 280 million, generating an investment income of RMB 5.2525 million in 2024 [99]. Research and Development - Research and development expenses increased by 1.77% year-on-year, reaching ¥40,783,991.67 in 2024, accounting for 2.82% of total revenue [68]. - The number of R&D personnel decreased by 13.30% from 188 in 2023 to 163 in 2024 [68]. - The company is investing in R&D, allocating 10% of its revenue towards developing new technologies [5]. Risk Management - The company faces risks from macroeconomic fluctuations and industry regulations, which could impact business development [120]. - The company faces operational risks due to fluctuations in raw material prices, including metals and electronic components, which are influenced by economic conditions and market supply and demand [122]. - The company has established long-term relationships with key suppliers to ensure stable raw material supply and is actively investing in raw material production to enhance its competitive advantage [122]. - The company has implemented measures to mitigate accounts receivable collection risks, focusing on projects with strong cash flow and clients with good credit [124]. - The company is expanding its overseas market presence to reduce reliance on any single country, while closely monitoring global political and economic conditions to minimize risks [126]. Employee and Talent Management - The total number of employees at the end of the reporting period is 1,410, including 96 from the parent company and 1,314 from major subsidiaries [170]. - The professional composition includes 935 production personnel, 331 technical personnel, and 22 sales personnel [171]. - The company adheres to the Labor Contract Law of the People's Republic of China, providing competitive salaries based on job roles and performance assessments [172]. - The company has actively enhanced its internal training programs to develop a high-quality talent pool [173]. Environmental and Social Responsibility - The company prioritizes environmental protection and promotes energy-saving activities, aiming to build a resource-saving and environmentally friendly enterprise [190]. - The company actively supports local employment by prioritizing hiring local workers for projects, contributing to local economic development [191]. - The company is committed to aligning economic benefits with social benefits, ensuring harmonious development with society [191]. Changes in Management - There were changes in the board of directors, with independent director Liu Weibing and deputy general manager Zhang Wenbin leaving due to term expiration [140]. - The company has appointed new independent director Zhao Junfeng and deputy general manager Liang Junhua as part of the board restructuring [141]. - The management team includes experienced professionals with backgrounds in finance, healthcare, and technology, enhancing the company's strategic direction [142].

Financial Performance - The company's operating revenue for Q1 2025 was ¥279,741,529.44, representing a 1.30% increase compared to ¥276,144,984.63 in the same period last year[3]. - Net profit attributable to shareholders was ¥13,964,187.65, a 0.58% increase from ¥13,883,489.34 year-on-year[3]. - The net profit after deducting non-recurring gains and losses surged by 84.75% to ¥11,703,692.54, up from ¥6,335,006.96 in the previous year[3]. - Total revenue for the current period reached ¥279,741,529.44, a slight increase from ¥276,144,984.63 in the previous period, reflecting a growth of approximately 0.58%[31]. - Net profit for the current period was ¥17,046,194.20, down from ¥18,356,313.59, indicating a decrease of approximately 7.1%[31]. Cash Flow - The net cash flow from operating activities increased by 77.68% to ¥97,711,706.95, compared to ¥54,991,837.20 in the same period last year[3]. - Operating cash inflow for the current period was CNY 470,623,931.49, an increase of 24.3% from CNY 378,556,228.14 in the previous period[33]. - Cash inflow from investment activities totaled CNY 608,251,544.21, significantly higher than CNY 330,821,994.53 in the previous period, marking an increase of 83.8%[33]. - Cash outflow from financing activities was CNY 267,684,358.89, compared to CNY 5,432,516.08 in the previous period, indicating a substantial increase in financing activities[33]. - The ending balance of cash and cash equivalents was CNY 373,500,006.05, down from CNY 563,864,314.81 in the previous period[33]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,589,202,654.05, a decrease of 7.44% from ¥3,877,889,089.89 at the end of the previous year[3]. - Total liabilities decreased to ¥800,116,008.49 from ¥1,102,046,421.18, a decrease of approximately 27.4%[29]. - The company's equity attributable to shareholders increased slightly by 0.34% to ¥2,648,123,535.33 from ¥2,639,101,461.32 at the end of the previous year[3]. Shareholder Information - The company reported a total of 58,323 common shareholders at the end of the reporting period[7]. - The top shareholder, Liang Guiqiu, holds 29.52% of the shares, totaling 249,586,723 shares[7]. Contracts and Projects - The company has significant ongoing contracts, including a project with a total contract value of ¥15,000,000 for the construction of a new hospital building in Henan Province, which is currently in the settlement phase[9]. - Another major contract is valued at ¥60,000,000 for the overall relocation project of a hospital in Shaanxi Province, also in the settlement phase[9]. - The company reported a completed project in Guangdong Province with a contract value of ¥37,611,190, which has passed acceptance inspection[9]. - The company is currently working on a project in Fujian Province with a contract value of ¥23,994,590, which is still under construction[9]. Legal and Arbitration Matters - The liquidation of Qinhuangdao Guangji Hospital Management Co., Ltd. has been initiated, with the assessed value of the liquidated assets confirmed at ¥117,751,800[12]. - The assets of Qinhuangdao Guangji Hospital Management Co., Ltd. were successfully auctioned for ¥52,383,924, resulting in the company losing ownership of these assets[14]. - The company has received an arbitration ruling for a total amount of ¥29,318,280 from Xuchang Second People's Hospital, which includes project payments, interest, and penalties[15]. - An additional arbitration case involving Xuchang Second People's Hospital has been accepted, with the amount involved being ¥6,368,610[16]. - The company is involved in a restructuring process for Xuchang Second People's Hospital and its affiliated entities, as mandated by the local court[17]. Impairment and Expenses - The company recognized a credit impairment loss of CNY 177.22 million based on the recoverable value data of all debts related to the municipal hospital[19]. - The company reported a credit impairment loss of ¥25,797,294.22, significantly higher than the previous period's loss of ¥5,405,350.21, marking an increase of over 377%[31]. - Research and development expenses rose significantly to ¥10,064,345.68 from ¥2,284,919.40, an increase of approximately 340%[31]. Convertible Bonds - The company issued 7.5 million convertible bonds with a total amount of CNY 750 million, which began trading on March 7, 2019[22]. - As of February 14, 2025, a total of 5,637,368 convertible bonds have been converted into 115,281,660 shares of the company[22]. - The total amount to be paid for the remaining convertible bonds that were not converted at maturity is CNY 204.89 million[23]. Accounting and Audit - The company did not undergo an audit for the first quarter report[34]. - The company is set to implement new accounting standards starting in 2025[35].

深圳市尚荣医疗股份有限公司 2024 年度内部控制自我评价报告 深圳市尚荣医疗股份有限公司 2024 年度内部控制自我评价报告 深圳市尚荣医疗股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简 称企业内部控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内 部控制日常监督和专项监督的基础上，我们对公司 2024 年 12 月 31 日的内部控制有效性进 行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并 如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行 监督。经理层负责组织领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、 高级管理人员保证本报告内容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容 的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真 实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅 能为实现上述目标提供合理保证。此外，由于 ...

深圳市尚荣医疗股份有限公司 2024年度监事会工作报告 2024 年，深圳市尚荣医疗股份有限公司（以下简称"公司"）监事会严格遵 守《公司法》、《证券法》及其他法律、法规、规章和《公司章程》及《公司监事 会议事规则》的规定，本着对全体股东负责的精神，认真履行有关法律、法规赋 予的职权，列席和出席了公司董事会和股东大会，积极有效地开展工作，对公司 依法运作情况和公司董事、高级管理人员履行职责情况进行监督，维护了公司及 股东的合法权益。现将监事会 2024 年主要工作报告如下： 一、监事会日常工作情况 报告期内，公司监事会共召开了 8 次监事会会议，会议的召开与表决程序均 符合《公司法》及《公司章程》等法律法规和规范性文件的规定。具体工作情况 如下： （一）2024年3月12日，公司召开第七届监事会第十一次临时会议，审议通 过了《关于公司为全资子公司向工商银行申请授信额度提供担保的议案》和《关 于公司为全资子公司向农业银行申请综合授信额度提供担保的议案》。 （二）2024年4月20日，公司召开第七届监事会第六次会议，《公司2023年 度监事会工作报告》 、《公司2023年度财务决算报告》、《公司2023年度利润 ...

深圳市尚荣医疗股份有限公司 董事会审计委员会对会计师事务所2024年度履行监督职责 情况的报告 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司治理 准则》、《国有企业、上市公司选聘会计师事务所管理办法》、《深圳证券交易所上 市公司自律监管指引第1号——主板上市公司规范运作》和《公司章程》等规定 和要求，深圳市尚荣医疗股份有限公司(以下简称"公司"或"本公司")董事会 审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将审计委员会对公司 2024年度年审会计师事务所履行监督职责的情况汇报如下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所的基本情况 机构名称：中审众环会计师事务所（特殊普通合伙）（以下简称"中审众环 会计师事务所"） 成立日期：中审众环会计师事务所始创于 1987 年，是全国首批取得国家批 准具有从事证券、期货相关业务资格及金融业务审计资格的大型会计师事务所之 一。根据财政部、证监会发布的从事证券服务业务会计师事务所备案名单，具备 股份有限公司发行股份、债券审计机构的资格。2013 年 11 月，按照国家财政部 等有关要求转制为特殊普通合伙制。 组织形式：特 ...

证券代码：002551 证券简称：尚荣医疗 公告编号：2025-023 截至 2024 年 12 月 31 日，公司公开发行可转换公司债券募集资金使用情况如下： | | | 深圳市尚荣医疗股份有限公司 关于2024年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据中国证监会发布的《上市公司监管指引第2号——上市公司募集资金管理和使用 的监管要求》和深圳证券交易所颁布的《深圳证券交易所股票上市规则》、《深圳证券交 易所上市公司自律监管指引第1号——主板上市公司规范运作》、《深圳证券交易所上市 公司自律监管指南第2号——公告格式》等有关规定，深圳市尚荣医疗股份有限公司（以 下简称"公司"或"本公司"），深圳市尚荣医疗股份有限公司（以下简称"公司"或"本公司"）董 事会编制了截至2024年度募集资金存放与实际使用情况的专项报告。 一、募集资金基本情况 1、根据中国证券监督管理委员会于 2018 年 12 月 5 日签发的证监许可[2018]1843 号文《关于核准深圳市尚荣医疗股份有限公司公开发行可转换公司债券的批复》深圳市尚 ...

深圳市尚荣医疗股份有限公司 2024年度董事会工作报告 2024 年，深圳市尚荣医疗股份有限公司（以下简称"公司"）董事会认真 履行《公司法》、《证券法》、《公司章程》及《董事会议事规则》等法律法规 及相关规定，严格执行股东大会决议，严格遵守证监会、深交所等监管机构要求， 充分发挥决策职能，推动公司治理水平的提高和公司各项业务的发展，积极有效 地发挥了董事会的作用。现将本届董事会 2024 年度的工作情况汇报如下： 一、2024 年主要经营指标情况 公司 2024 年度实现营业总收入 144,820.63 万元，比上年同期增长 21.40%； 实现营业利润 3,353.73 万元，比上年同期增长 127.67%；实现归属于上市公司 股东的净利润 2,228.20 万元，比上年同期增加 114.97%；截至 2024 年 12 月 31 日，公司资产总额 387,788.91 万元，负债总额 110,204.64 万元，归属于母公司 股东权益为 263,910.15 万元，资产负债率 28.42%。 二、董事会工作情况 （一）规范董事会运行机制 1、董事会会议情况 报告期内，公司董事会共召开会议12次。董事会的 ...

本次会计政策变更是根据财政部发布的《企业会计准则解释第 18 号》（财会〔2024〕 24 号）（以下简称"《准则解释第 18 号》"）的相关规定要求进行的相应变更，根据《上 市公司自律监管指引第 1 号—主板上市公司规范运作》的相关规定，本次会计政策变更 无需提交深圳市尚荣医疗股份有限公司（以下简称"公司"）董事会和股东大会审议批 准；本次会计政策变更不会对公司财务状况、经营成果和现金流量产生重大影响。 一、本次会计政策变更概述 1、会计政策变更的原因 2024 年 12 月，财政部发布《企业会计准则解释第 18 号》（财会〔2024〕24 号）， 规定对于不属于单项履约义务的保证类质量保证，企业应当按照《企业会计准则第 13 号——或有事项》（财会〔2006〕3 号）有关规定，按确定的预计负债金额，借记"主营 业务成本""其他业务成本"等科目，贷记"预计负债"科目，并相应在利润表中的 "营业成本"和资产负债表中的"其他流动负债"、"一年内到期的非流动负债"、 "预计负债"等项目列示。该解释规定自印发之日起施行，允许企业自发布年度提前执 行。由于上述会计准则解释的发布，公司需对会计政策进行相应变更，并自 2 ...